Matt Hoffman

Invivyd has dosed the first participants in LIBERTY, a phase 3 trial comparing VYD2311 to an mRNA COVID vaccine and coadministration, as the BLA-enabling DECLARATION trial completes enrollment.

Joanne D. Stekler, MD, MPH, discusses why many Americans still miss HIV diagnosis—and how opt-out screening, rapid tests, self-tests, and same-day treatment close the gap.

Why people with HIV age faster: Kristine Erlandson, MD, offers expert tips on frailty, HAND screening, statins post-REPRIEVE, and avoiding ART drug interactions.

The FDA has approved bulevirtide-gmod (Hepcludex), the first approved US therapy for HDV with no prior treatment options.

A study assessing the local transmission found it caused 14 confirmed cases in 2024 and exposed diagnostic delays in patients without travel history.

The FDA’s biologics center faces another leadership shake-up as Vinay Prasad, MD, MPH, plans an exit in April, leaving questions over vaccine rules and gene-therapy approvals.

After delays in the review of the COVID-19 vaccine—which missed its April 1 review deadline—the agency has requested new data.

The official cause of death is still under investigation by the New Mexico Office of the Medical Investigator, though the individual tested positive for the measles virus.

A serious adverse event of motor neuropathy reported in September 2024 has resulted in a hold on the investigational new drug application.

The Public Health Agency of Sweden reported the individual sought care at Region Stockholm and has been diagnosed with mpox caused by clade I.

The test was validated as part of the NIH’s RADx tech program through its Independent Test Assessment Program, in collaboration with the FDA.

A newly published study suggests that a 15-day regimen, while safe, did not statistically separate from a placebo comparator group in main outcomes for PASC of SARS-CoV-2 infection.

Ongoing surveillance from the CDC and FDA will continue to evaluate the risk of Guillan-Barré syndrome to guide further ACIP recommendations.

Despite the disproportionate effects of SARS-CoV-2 infection and severe outcomes on nursing home residents, less than 50% have received the updated 2023/2024 vaccine.

The study findings imply newly available prevention strategies for which older children—ages 2 to 5 years—are not currently eligible should be prioritized.

New research has suggested that Alzheimer disease pathology may be driven by an infectious agent, Porphyromonas gingivalis.

Congress has voted to pass the right-to-try bill, which will provide terminally ill patients with the ability to seek out experimental therapies not yet approved by the FDA.

Investigational beta-lacatamase inhibitor IMI/REL demonstrates a favorable overall response against certain imipenem-non-susceptible bacterial infections.

At CROI 2018, Dr. Patricia Flynn discussed the impact of ART on individuals with perinatal HIV infections, and how far the infectious disease community has come since its initial use.

The medical community has learned many lessons by looking back on the early days of the HIV/AIDS epidemic, including the value of multidisciplinary teams, the vital role of acute care clinicians, and more.

Amid alleged tobacco investments, Brenda Fitzgerald has resigned from her position as director of the CDC.

Can a prior pharmaceutical company president successfully address ever-climbing medication costs in the United States?

The test combines the convenience of the saliva test with the reliability of the blood test.

The FDA recently issued a Compounding Risk Alert related to a rare, adverse event associated with compounded triamcinolone, moxifloxacin, and vancomycin: potential blindness.